Emricasan (IDN-6556)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Emricasan (IDN-6556)	Purity：99% min
CAS NO：254750-02-2	Solubility：DMSO : ≥ 42 mg/mL (73.75 mM)
Molecular Formula：C₂₆H₂₇F₄N₃O₇	Package：Package according to customer requirements
Molecular Weight：569.502	Storage：Store at -20℃

Quality control

Remarks

Emricasan, also known as IDN 6556 and PF 03491390, is a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases. Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral IDN-6556 may lower aminotransferase activity in patients with chronic hepatitis C. Orally-administered PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model.

Antiviral Inhibitors Related Products:

Vadimezan; Geldanamycin; UNC0638; U0126-EtOH; Tenofovir; Baloxavir; Tubacin; NGI-1(ML414); Remdesivir; Baloxavir marboxil; Famciclovir; Epigoitrin ; Ribavirin

References

[1]. Barreyro FJ, et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. Liver Int. 2015 Mar;35(3):953-66.

[2]. Hoglen NC, et al. Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-te trafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor. J Pharmacol Exp Ther. 2004 May;309(2):634-40.